LOCALLY ADVANCED RECTAL CANCER (LARC)
Clinical trials for LOCALLY ADVANCED RECTAL CANCER (LARC) explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL CANCER (LARC) trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL CANCER (LARC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to shrink rectal tumors and avoid surgery
Disease control Not yet recruitingThis study tests two treatment plans for people with high-risk locally advanced rectal cancer. One group gets short-course radiation followed by chemo plus an immunotherapy drug. The other gets long-course chemoradiation followed by chemo. The goal is to see which approach better…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
New drug cocktail aims to shrink Hard-to-Treat GI cancers
Disease control Not yet recruitingThis study tests a combination of two drugs (zanidatamab and tislelizumab) plus chemotherapy or radiation in people with HER2-positive gastrointestinal cancers, including rectal, stomach, and colorectal cancers. The goal is to see if this treatment can shrink tumors before surger…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
New combo therapy aims to shrink rectal tumors and avoid surgery
Disease control Not yet recruitingThis study tests a new approach for people with locally advanced rectal cancer that is not responsive to immunotherapy alone. Participants first receive short-course radiation, then a combination of an experimental immunotherapy drug (QL1706) and chemotherapy. The goal is to shri…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
New combo could let some rectal cancer patients avoid surgery
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (XELOX) after chemoradiation helps shrink advanced rectal cancer more than chemotherapy alone. About 270 adults with a specific type of rectal cancer (pMMR/MSS or MSI-Low) will take part. …
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
Could a diabetes drug boost rectal cancer treatment?
Disease control Not yet recruitingThis study tests whether adding a weight-loss medication (GLP-1 drug) to standard chemotherapy and radiation before surgery helps rectal cancer patients with a high BMI. About 42 participants will either receive the drug plus standard therapy or standard therapy alone. Researcher…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: St. James's Hospital, Ireland • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New combo therapy aims to boost rectal cancer remission without surgery
Disease control Not yet recruitingThis study tests a new treatment plan for people with a certain type of advanced rectal cancer. The approach combines a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before any surgery. The goal is to see if this combination can make the tumor d…
Matched conditions: LOCALLY ADVANCED RECTAL CANCER (LARC)
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 20, 2026 11:55 UTC